Each touch point presents an opportunity to connect with patients and influence behavior. Triplefin collaborates with brand teams to build successful access and adherence programs that help enhance the patient experience, decrease prescription abandonment and drive your brand’s success through every phase of the journey.
Over the past 10 years, the healthcare industry has experienced tremendous changes. From payment reform, provider consolidation, increased regulation of the industry, and an increased focus on quality and outcomes; every aspect of the healthcare system has been affected. For some manufacturers, this creates questions on how to navigate within this new environment.
Manufacturers are faced with brand challenges for smaller molecule drugs that have a broad patient population that comprise the 'middle market' between traditional, retail drugs and higher cost specialty drugs, referred to as Specialty-Lite™. These drugs require high touch patient services that are beyond general education, such as benefit investigation, prior authorization and patient advocate coaching to maintain therapy and promote adherence.
Triplefin has the expertise needed to support this growing population with its Hub-Lite® model, offering flexible, end-to-end services that are cost effective and deliver the highest level of patient support.
Using a customizable program driven by its suite of digital solutions, Rx365®, Triplefin incorporates a modular design that allows brands to add self-serving functionality for reimbursement, benefit verification, prior authorization, card activation, home delivery and CRM options.
This open architecture enhances the overall patient experience, creating many opportunities for engagement that maximize profitable access and drive demand for pharmaceutical brands.
“I hope you know what an excellent and wonderful employee you have in Myko and what a wonderful person she is. That it is rare that you find someone that will go that extra mile. Whatever you do, do not let her go.” — Patient